Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drugs in Development, 2021
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drugs in Development, 2021
SUMMARY
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostaglandin E2 Receptor EP4 Subtype - Drugs In Development, 2021, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 13 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Musculoskeletal Disorders, Respiratory, Women's Health, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Colorectal Cancer, Gastric Cancer, Solid Tumor, Autoimmune Disorders, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Rectal Cancer, Triple-Negative Breast Cancer (TNBC), Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Osteoarthritis, Pain, Allergies, Asthma, Bladder Cancer, Bone Defects, Breast Cancer, Cervical Cancer, Colon Cancer, Delirium, Esophageal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Bowel Disease, Inflammatory Pain, Liver Cancer, Lung Adenocarcinoma, Melanoma, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Neuroinflammation, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Pancreatic Cancer, Pneumonia, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified and Unspecified Cancer.
Furthermore, this report also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostaglandin E2 Receptor EP4 Subtype - Drugs In Development, 2021, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 13 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Musculoskeletal Disorders, Respiratory, Women's Health, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Colorectal Cancer, Gastric Cancer, Solid Tumor, Autoimmune Disorders, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Rectal Cancer, Triple-Negative Breast Cancer (TNBC), Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Osteoarthritis, Pain, Allergies, Asthma, Bladder Cancer, Bone Defects, Breast Cancer, Cervical Cancer, Colon Cancer, Delirium, Esophageal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Bowel Disease, Inflammatory Pain, Liver Cancer, Lung Adenocarcinoma, Melanoma, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Neuroinflammation, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Pancreatic Cancer, Pneumonia, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified and Unspecified Cancer.
Furthermore, this report also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
AskAt Inc
Domain Therapeutics SA
Eisai Co Ltd
Exalys Therapeutics Inc
GlaxoSmithKline Plc
Gurus BioPharm
Kaken Pharmaceutical Co Ltd
Kanaph Therapeutics Inc
Medibiofarma SL
Mesentech Inc
NB Health Laboratory Co Ltd
Ono Pharmaceutical Co Ltd
RaQualia Pharma Inc
Rottapharm Biotech Srl
Shanghai Bioray Laboratory Inc
Sosei Group Corp
TempestTx, Inc.
Teon Therapeutics Inc
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
AAT-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BYD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-6086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize EP4 for Delirium and NeuroInflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-095895 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
grapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-726701A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GUR-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAG-308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KNP-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBF-251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MES-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MES-1088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4578 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palupiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize EP4 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Prostanoid EP4 Receptor for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-1495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-038 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
Featured News & Press Releases
Aug 24, 2020: Adlai Nortye announces first patient dosed in phase 1b clinical trial of AN0025 (EP4 Antagonist) in combination with Merck's KEYTRUDA (pembrolizumab) for advanced solid tumors
Jan 30, 2020: Tempest Therapeutics announces FDA clearance of investigational new drug application for TPST-1495 and welcomes new investors
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People's Republic of China
Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea
Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress
Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress
Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)
Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
AskAt Inc
Domain Therapeutics SA
Eisai Co Ltd
Exalys Therapeutics Inc
GlaxoSmithKline Plc
Gurus BioPharm
Kaken Pharmaceutical Co Ltd
Kanaph Therapeutics Inc
Medibiofarma SL
Mesentech Inc
NB Health Laboratory Co Ltd
Ono Pharmaceutical Co Ltd
RaQualia Pharma Inc
Rottapharm Biotech Srl
Shanghai Bioray Laboratory Inc
Sosei Group Corp
TempestTx, Inc.
Teon Therapeutics Inc
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
AAT-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BYD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-6086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize EP4 for Delirium and NeuroInflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-095895 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
grapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-726701A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GUR-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAG-308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KNP-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBF-251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MES-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MES-1088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4578 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palupiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize EP4 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Prostanoid EP4 Receptor for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-1495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-038 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
Featured News & Press Releases
Aug 24, 2020: Adlai Nortye announces first patient dosed in phase 1b clinical trial of AN0025 (EP4 Antagonist) in combination with Merck's KEYTRUDA (pembrolizumab) for advanced solid tumors
Jan 30, 2020: Tempest Therapeutics announces FDA clearance of investigational new drug application for TPST-1495 and welcomes new investors
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People's Republic of China
Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea
Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress
Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress
Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)
Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AskAt Inc, 2021
Pipeline by Domain Therapeutics SA, 2021
Pipeline by Eisai Co Ltd, 2021
Pipeline by Exalys Therapeutics Inc, 2021
Pipeline by GlaxoSmithKline Plc, 2021
Pipeline by Gurus BioPharm, 2021
Pipeline by Kaken Pharmaceutical Co Ltd, 2021
Pipeline by Kanaph Therapeutics Inc, 2021
Pipeline by Medibiofarma SL, 2021
Pipeline by Mesentech Inc, 2021
Pipeline by NB Health Laboratory Co Ltd, 2021
Pipeline by Ono Pharmaceutical Co Ltd, 2021
Pipeline by RaQualia Pharma Inc, 2021
Pipeline by Rottapharm Biotech Srl, 2021
Pipeline by Shanghai Bioray Laboratory Inc, 2021
Pipeline by Sosei Group Corp, 2021
Pipeline by TempestTx, Inc., 2021
Pipeline by Teon Therapeutics Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AskAt Inc, 2021
Pipeline by Domain Therapeutics SA, 2021
Pipeline by Eisai Co Ltd, 2021
Pipeline by Exalys Therapeutics Inc, 2021
Pipeline by GlaxoSmithKline Plc, 2021
Pipeline by Gurus BioPharm, 2021
Pipeline by Kaken Pharmaceutical Co Ltd, 2021
Pipeline by Kanaph Therapeutics Inc, 2021
Pipeline by Medibiofarma SL, 2021
Pipeline by Mesentech Inc, 2021
Pipeline by NB Health Laboratory Co Ltd, 2021
Pipeline by Ono Pharmaceutical Co Ltd, 2021
Pipeline by RaQualia Pharma Inc, 2021
Pipeline by Rottapharm Biotech Srl, 2021
Pipeline by Shanghai Bioray Laboratory Inc, 2021
Pipeline by Sosei Group Corp, 2021
Pipeline by TempestTx, Inc., 2021
Pipeline by Teon Therapeutics Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
